9-Chloro-2-[[5-[3-(dimethylamino)propyl]pyridin-3-yl]amino]-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one | 1228961-85-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 9-Chloro-2-[[5-[3-(dimethylamino)propyl]pyridin-3-yl]amino]-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one
• 英文别名: 9-chloro-2-[[5-[3-(dimethylamino)propyl]pyridin-3-yl]amino]-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one
• CAS: 1228961-85-0
• 化学式: C₂₂H₂₃ClN₆O
• 分子量: 422.917
• InChiKey: LEEUHHYOIOXHPK-UHFFFAOYSA-N

物化性质

• 密度：
  1.306±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  83
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  9-Chloro-2-[[5-[3-(dimethylamino)propyl]pyridin-3-yl]amino]-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one 在 吡啶 、 tetraphosphorus decasulfide 作用下， 以20%的产率得到9-chloro-2-({5-[3-(dimethylamino)propyl]pyridin-3-yl}amino)-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepine-6-thione
  参考文献：
  名称：

  Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905)

  摘要：

  This article describes the discovery of a series of potent inhibitors of Polo-like kinase 1 (PLK1). Optimization of this benzolactam-derived chemical series produced an orally bioavailable inhibitor of PLK1 (12c, MLN0905). In vivo pharmacokinetic-pharmacodynamic experiments demonstrated prolonged mitotic arrest after oral administration of 12c to tumor bearing nude mice. A subsequent efficacy study in nude mice achieved tumor growth inhibition or regression in a human colon tumor (HT29) xenograft model.

  DOI：

  10.1021/jm2011172
• 作为产物：
  描述：

  8-chloro-2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]azepine-4-carboxylic acid methyl ester 在 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium 10% on activated carbon 、 水 、 氢气 、 potassium carbonate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二甲基亚砜 为溶剂， 反应 2.5h， 生成 9-Chloro-2-[[5-[3-(dimethylamino)propyl]pyridin-3-yl]amino]-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one
  参考文献：
  名称：

  Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905)

  摘要：

  This article describes the discovery of a series of potent inhibitors of Polo-like kinase 1 (PLK1). Optimization of this benzolactam-derived chemical series produced an orally bioavailable inhibitor of PLK1 (12c, MLN0905). In vivo pharmacokinetic-pharmacodynamic experiments demonstrated prolonged mitotic arrest after oral administration of 12c to tumor bearing nude mice. A subsequent efficacy study in nude mice achieved tumor growth inhibition or regression in a human colon tumor (HT29) xenograft model.

  DOI：

  10.1021/jm2011172

文献信息

• THIOLACTAMS AND USES THEREOF
  申请人：Bharathan Indu T.

  公开号：US20120309743A1

  公开（公告）日：2012-12-06

  This invention provides compounds of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

  该发明提供了I式化合物：其中R1、R2、R3、R4、R5和R6如规范中所述。这些化合物是PLK的抑制剂，因此可用于治疗增殖性、炎症性或心血管疾病。
• 5,7-DIHYDRO-6H-PYRIMIDO[5,4-D][1]BENZAZEPIN-6-THIONES AS PLK INHIBITORS
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP2373657B1

  公开（公告）日：2016-09-14
• US8507667B2
  申请人：——

  公开号：US8507667B2

  公开（公告）日：2013-08-13
• Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905)
  作者：Matthew O. Duffey、Tricia J. Vos、Ruth Adams、Jennifer Alley、Justin Anthony、Cynthia Barrett、Indu Bharathan、Douglas Bowman、Nancy J. Bump、Ryan Chau、Courtney Cullis、Denise L. Driscoll、Amy Elder、Nancy Forsyth、Jonathan Frazer、Jianping Guo、Luyi Guo、Marc L. Hyer、David Janowick、Bheemashankar Kulkarni、Su-Jen Lai、Kerri Lasky、Gang Li、Jing Li、Debra Liao、Jeremy Little、Bo Peng、Mark G. Qian、Dominic J. Reynolds、Mansoureh Rezaei、Margaret Porter Scott、Todd B. Sells、Vaishali Shinde、Qiuju Judy Shi、Michael D. Sintchak、Francois Soucy、Kevin T. Sprott、Stephen G. Stroud、Michelle Nestor、Irache Visiers、Gabriel Weatherhead、Yingchun Ye、Natalie D’Amore

  DOI：10.1021/jm2011172

  日期：2012.1.12

  This article describes the discovery of a series of potent inhibitors of Polo-like kinase 1 (PLK1). Optimization of this benzolactam-derived chemical series produced an orally bioavailable inhibitor of PLK1 (12c, MLN0905). In vivo pharmacokinetic-pharmacodynamic experiments demonstrated prolonged mitotic arrest after oral administration of 12c to tumor bearing nude mice. A subsequent efficacy study in nude mice achieved tumor growth inhibition or regression in a human colon tumor (HT29) xenograft model.